Novel Epidermal Growth Factor Receptor (ErbB-3) And Antibodies
Description of Invention:
ErbB-3 is a member of the type I family of growth factor receptors. ErbB-3 is a 148 kd transmembrane polypeptide which has between 64-67% homology to contiguous regions within the tyrosine kinase domains of the EGFR and erbB-2 proteins, respectively. ErbB-3 has been mapped to human chromosome 12 ql 11-13 and has been shown to be expressed as a 6.2 kb transcript in a variety of normal tissues of epithelial origin. Markedly elevated erbB-3 mRNA levels have been demonstrated in certain human mammary tumor cell lines. These findings suggest that increased erbB-3 expression may play a role in oncogenesis.
U.S. Patent 5,183,884 includes claims to the cDNA encoding erbB-3, vectors containing the cDNA and cells transformed with the vector containing the cDNA encoding erbB-3. The DNA can be used in diagnostic applications or for production of the protein.
U.S. Patent 5,480,968 includes claims to the erbB-3 protein and antibodies to erbB-3. Such antibodies include both monoclonal and polyclonal antibodies. The antibodies may be labeled allowing for detection of erbB-3, or conjugated with a cytotoxic agent for use as a therapeutic.
The divisional applications, U.S. Patent No. 5,820,859 and U.S. Patent No. 5,916,755, include claims to DNA and antibody based diagnostic methods, drug screening assays, therapeutic applications utilizing antibody conjugates or ligands which block the binding of an activating ligand to erbB-3; activating or blocking ligands which bind to erbB-3.
Inventors:
M Kraus (NCI) SA Aaronson (NCI)
Patent Status:
DHHS Reference No. E-221-1989/0 --
U.S. Patent No. 5,183,884 issued 02 Feb 1993
DHHS Reference No. E-221-1989/1 --
U.S. Patent No. 5,480,968 issued 02 Jan 1996
U.S. Patent No. 5,820,859 issued 13 Oct 1998
U.S. Patent No. 5,916,755 issued 29 Jun 1999
U.S. Patent No. 6,639,060 issued 28 Oct 2003
U.S. Patent Application No. 10/693,030 filed 24 Oct 2003
Portfolios: Cancer
Cancer -Diagnostics-In Vitro-MAb Based Cancer -Diagnostics-In Vivo-MAb Cancer -Therapeutics-Immunoconjugates-Mab Cancer -Diagnostics Cancer -Therapeutics Cancer -Research Materials
For Additional Information Please Contact: Susan S. Rucker J.D.
NIH Office of Technology Transfer
6011 Executive Blvd, Suite 325
Rockville, MD 20852-3804
Phone: (301) 435-4478
Email: ruckersu@mail.nih.gov
Fax: (301) 402-0220
